학술논문
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Document Type
article
Author
Hans Salwender; Niels Weinhold; Axel Benner; Kaya Miah; Maximilian Merz; Mathias Haenel; Christian Jehn; Elias Mai; Ekaterina Menis; Igor Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Steffen Luntz; Britta Besemer; Markus Munder; Peter Brossart; Bertram Glass; Hans-Walter Lindemann; Katja Weisel; Christine Hanoun; Paul Schnitzler; Sarah Klemm; Hartmut Goldschmidt; Marc Raab; Ahmet Elmaagacli
Source
Hematology, Vol 29, Iss 1 (2024)
Subject
Language
English
ISSN
16078454
1607-8454
1607-8454
Abstract
ABSTRACTObjectives The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.Methods Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.Results CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS.Discussion Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.